

Cardiovascular End Points and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components

Qi-Fang Huang,* Lucas S. Aparicio,* Lutgarde Thijs, Fang-Fei Wei, Jesus D. Melgarejo, Yi-Bang Cheng, Chang-Sheng Sheng, Wen-Yi Yang, Natasza Gilis-Malinowska, José Boggia, Teemu J. Niiranen, Wiktoria Wojciechowska, Katarzyna Stolarz-Skrzypek, Jessica Barochiner, Daniel Ackermann, Valérie Tikhonoff, Belen Ponte, Menno Pruijm, Edoardo Casiglia, Krzysztof Narkiewicz, Jan Filipovský, Danuta Czarnecka, Kalina Kawecka-Jaszcz, Antti M. Jula, Murielle Bochud, Thomas Vanassche, Peter Verhamme, Harry A.J. Struijker-Boudier, Ji-Guang Wang, Zhen-Yu Zhang,† Yan Li,† Jan A. Staessen[‡]; the IDCARS (International Database of Central Arterial Properties for Risk Stratification) Investigators[‡]

Abstract—Pulsatile blood pressure (BP) confers cardiovascular risk. Whether associations of cardiovascular end points are tighter for central systolic BP (cSBP) than peripheral systolic BP (pSBP) or central pulse pressure (cPP) than peripheral pulse pressure (pPP) is uncertain. Among 5608 participants (54.1% women; mean age, 54.2 years) enrolled in nine studies, median follow-up was 4.1 years. cSBP and cPP, estimated tonometrically from the radial waveform, averaged 123.7 and 42.5 mmHg, and pSBP and pPP 134.1 and 53.9 mmHg. The primary composite cardiovascular end point occurred in 255 participants (4.5%). Across fourths of the cPP distribution, rates increased exponentially (4.1, 5.0, 7.3, and 22.0 per 1000 person-years) with comparable estimates for cSBP, pSBP, and pPP. The multivariable-adjusted hazard ratios, expressing the risk per 1-SD increment in BP, were 1.50 (95% CI, 1.33–1.70) for cSBP, 1.36 (95% CI, 1.19–1.54) for cPP, 1.49 (95% CI, 1.33–1.67) for pSBP, and 1.34 (95% CI, 1.19–1.51) for pPP ($P < 0.001$). Further adjustment of cSBP and cPP, respectively, for pSBP and pPP, and vice versa, removed the significance of all hazard ratios. Adding cSBP, cPP, pSBP, pPP to a base model including covariables increased the model fit ($P < 0.001$) with generalized R^2 increments ranging from 0.37% to 0.74% but adding a second BP to a model including already one did not. Analyses of the secondary end points, including total mortality (204 deaths), coronary end points (109) and strokes (89), and various sensitivity analyses produced consistent results. In conclusion, associations of the primary and secondary end points with

Received February 7, 2020; first decision February 24, 2020; revision accepted June 3, 2020.

From the Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital (Q.-F.H., Y.-B.C., C.-S.S., J.-G.W., Y.L.), Department of Cardiology, Shanghai General Hospital (W.-Y.Y.), Shanghai Jiao Tong University School of Medicine, China; Servicio de Clínica Médica, Sección Hipertensión Arterial, Hospital Italiano de Buenos Aires, Argentina (L.S.A., J.B.); Research Unit Hypertension and Cardiovascular Epidemiology (L.T., F.-F.W., J.D.M., Z.-Y.Z., J.A.S.) and Centre for Molecular and Vascular Biology (T.V., P.V.), KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium; Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdańsk, Poland (N.G.-M., K.N.); Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.); Population Studies Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Turku, Finland (T.J.N., A.M.J.); Department of Medicine, Turku University Hospital and University of Turku, Finland (T.J.N.); First Department of Cardiology, Interventional Electrophysiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland (W.W., K.S.-S., D.C., K.K.-J.); Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland (D.A.); Department of Medicine, University of Padua, Italy (V.T., E.C.); Division of Nephrology, University Hospital of Geneva, Geneva, Switzerland (B.P.); Center for Primary Care and Public Health (B.P.) and Center for Primary Care and Public Health (M.B.), Unisanté, University of Lausanne, Switzerland; Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Switzerland (M.P.); Faculty of Medicine, Charles University, Pilsen, Czech Republic (J.F.); Department of Pharmacology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, the Netherlands (H.A.J.S.-B.); and NPA Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium (J.A.S.).

*These authors contributed equally to this work as co-first authors.

†These authors contributed equally to this work as co-last authors.

‡A list of all the IDCARS (International Database of Central Arterial Properties for Risk Stratification) Investigators is given in the Appendix.

This paper was sent to Suzanne Oparil, Consulting Editor, for review by expert referees, editorial decision, and final disposition

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.120.14787>.

Correspondence to Yan Li, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Rd 197 Shanghai 200025, China, Email liyanshen@163.com or Jan A. Staessen, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Campus Sint Rafaël, Kapucijnenvoer 35, Box 7001, BE-3000 Leuven, Belgium, Email jan.staessen@med.kuleuven.be

© 2020 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

SBP and pulse pressure were not stronger if BP was measured centrally compared with peripherally. (*Hypertension*. 2020;76:350-358. DOI: 10.1161/HYPERTENSIONAHA.120.14787.) • [Data Supplement](#)

Key Words: blood pressure ■ morbidity ■ mortality ■ population ■ risk

Blood pressure (BP) is the main modifiable cardiovascular risk factor.¹ Diastolic and mean arterial BP (MAP), the steady BP components, drive blood flow and are similar throughout the arterial tree from the ascending aorta up to the small arterioles, running through vital organs.² Systolic BP and pulse pressure (PP), the difference between systolic and diastolic BP oscillate around MAP, make up the pulsatile component of BP. Over half a century of research established systolic BP and PP as cardiovascular risk factor, in particular, in older adults.² Placebo-controlled randomized trials in patients with isolated systolic hypertension proved that lowering systolic BP reduced overall cardiovascular risk by over 30%.³ Over the human lifespan, PP becomes wider because aging and age-related morbid conditions, such as hypertension, diabetes mellitus, or chronic kidney disease degrade the elastic properties of large arteries.² Widening of PP at any age is predominantly associated with a larger forward pressure wave,⁴ thereby increasing the load on the left ventricle,⁵ causing target organ damage,⁶ and ultimately cardiovascular complications.⁶

Central systolic BP and central PP are lower than their peripheral counterparts are.² The perception that the pulsatile BP component confers risk and the anatomic proximity of the aorta to the heart, brain, and kidney, gave rise to the hypothesis that cardiovascular complications must be more closely associated with central than peripheral systolic BP and PP.⁷ However, the evidence supporting a tighter association of cardiovascular end points with central than peripheral BP, remains controversial.⁷ To address this knowledge gap, we constructed the IDCARS (International Database of Central Arterial Properties for Risk Stratification), in which data from nine prospective population studies were harmonized and analyzed. In this article, we compared associations of fatal and nonfatal cardiovascular end points with central and peripheral systolic BP and PP.

Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study Participants

All population studies included in IDCARS received ethical approval in their country of origin and adhered to the principles of the Declaration of Helsinki. Participants provided written informed consent. The anonymized IDCARS database was constructed at the Studies Coordinating Centre in Leuven, Belgium. IDCARS cohorts qualified for inclusion in the present analysis, if peripheral and central BP and cardiovascular risk factors had been measured at baseline, and if follow-up included both fatal and nonfatal outcomes. The [Data Supplement](#) available online provide detailed information on the population sampling methods, timelines, and countries of recruitment (Table S1 in the [Data Supplement](#)). Initial enrollment took place from 1985 until 2015. For the present analysis, baseline refers to the first measurement of central and peripheral BP along with cardiovascular risk factors (October 2000 until February 2016). Across studies, the last follow-up took place from October 2012 to December 2018

(Table S1). References describing the nine cohorts are available in Table S2 and References S1 to S23 in the [Data Supplement](#).

BP Measurement

Peripheral BP was measured immediately before the hemodynamic assessment after participants had rested for at least 5 minutes in the supine position, using standard mercury sphygmomanometers or validated oscillometric devices (Table S3). Peripheral BP was the average or the last of 2 consecutive readings. MAP was peripheral diastolic BP plus one-third of PP. Estimates of central BP were calibrated on peripheral systolic and diastolic BP. Experienced observers recorded the radial arterial waveform at the dominant arm during an 8-second period by applanation tonometry. They used a high-fidelity SPC-301 micromanometer (Millar Instruments Inc., Houston, TX), interfaced with a SphygmoCor CvMS device and a laptop computer running SphygmoCor software. Recordings were discarded if the systolic or diastolic variability of consecutive waveforms exceeded 5% or if the amplitude of the pulse wave signal was below 80 mV, or if the operator index was <70%. From the radial signal, the SphygmoCor software reconstructs the aortic pulse wave by means of a validated generalized transfer function.⁸ The software returns systolic, diastolic, MAP, and PP in the ascending aorta.

Ascertainment of End Points

We ascertained vital status and the incidence of fatal and nonfatal end points from the appropriate sources in each country. Prespecified end points were coded according to the *International Classification of Diseases* (Table S4). The primary end point was a composite cardiovascular outcome consisting of cardiovascular mortality and nonfatal end points, including myocardial infarction, heart failure, stroke, and coronary revascularization. Secondary end points included total mortality, fatal and nonfatal coronary end points, and fatal and nonfatal stroke, not including transient ischemic attack. All end points were validated against hospital files or medical records held by primary care physicians or specialists. In all outcome analyses, only the first event within each category was considered. No participant was lost to follow-up.

Statistical Analysis

For database management and statistical analysis, we used SAS software, version 9.4, maintenance level 5. For between-group comparison of means and proportions, we applied the large-sample *Z* test and the Fisher exact test, respectively. After stratification for cohort and sex, we interpolated missing values of body mass index, serum creatinine, and blood glucose from the regression slopes on age. In participants with unknown status of smoking or drinking, we set the indicator (dummy) variable to the cohort- and sex-specific mean of the codes (0, 1). For the cohort recruited in Buenos Aires, Argentina, we extrapolated alcohol consumption from national statistics stratified by sex and age.⁹ To compute 95% CIs of rates, we applied the formula as $R \pm 1.96 \times \sqrt{(R/T)}$, where *R* and *T* are the rate and the number of individuals used to compute the rate.

In multivariable-adjusted Cox regression, we accounted for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking status, the ratio of total-to-HDL (high-density lipoprotein) serum cholesterol, the estimated glomerular filtration rate (Chronic Kidney Disease-Epidemiology Collaboration equation), antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus. To adjust for cohort, we pooled participants recruited in the framework of the European Project on Genes in Hypertension (Kraków, Pilsen, and Padova;

Table 1. Baseline Characteristics of Participants

Characteristic	Statistic (n=5608)
Number (%) with characteristic	
Women	3034 (54.1)
Europeans	2388 (42.6)
Asians	1823 (32.5)
South Americans	1397 (24.9)
Current smoking*	1179 (21.0)
Drinking alcohol*	2818 (50.3)
Office hypertension†	2987 (53.3)
On antihypertensive treatment*	1943 (34.7)
Diabetes mellitus*	338 (6.03)
History of cardiovascular disease*	792 (14.1)
Renal dysfunction‡	700 (12.5)
Mean (±SD) of characteristic	
Age, y	54.2±14.4
Body mass index, kg/m ²	25.8±4.8
Peripheral blood pressure, mm Hg†	
Systolic / diastolic, mm Hg	134.1±21.0/80.2±10.7
Pulse pressure, mm Hg	53.9±16.3
Central blood pressure, mm Hg§	
Systolic / diastolic, mm Hg	123.7±21.2/81.2±10.9
Pulse pressure, mm Hg	42.5±16.1
Mean arterial blood pressure, mm Hg	99.3±13.8
Biochemistry	
Serum total cholesterol, mg/dL	195.4±38.9
Serum HDL cholesterol, mg/dL	57.5±15.2
Serum non-HDL cholesterol, mg/dL	137.9±39.2
Total-to-HDL cholesterol ratio	3.60±1.11
Serum creatinine, mg/dL	0.93±0.28
Glomerular filtration rate, mL/(min·1.73 m ²)‡	82.5±19.6
Blood glucose, mg/dL	90.7±19.2

HDL indicates high-density lipoprotein.

*Assessed by questionnaire at baseline. Current smoking was inhaling tobacco smoke on a daily basis. Drinking alcohol was the occasional or daily consumption of ethanol-containing beverages. Diabetes mellitus was use of antidiabetic drugs, fasting blood glucose of ≥ 126 mg/dL, random blood glucose of ≥ 200 mg/dL, a self-reported diagnosis, or diabetes mellitus documented in practice or hospital records.

†Peripheral blood pressure was measured immediately before the hemodynamic assessment after participants had rested in the supine position for ≥ 5 min with participants, using standard mercury sphygmomanometers or validated oscillometric devices. Hypertension was a blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic, or use of antihypertensive drugs.

‡The glomerular filtration rate was derived from serum creatinine using the Chronic Kidney Disease–Epidemiology Collaboration formula. Renal dysfunction was a glomerular filtration rate < 60 mL/(min·1.73 m²).

§Central blood pressure was measured tonometrically (Table S3).

||Measured at baseline by automated enzymatic methods in certified laboratories.

Table S1). We checked the proportional hazards assumption by the Kolmogorov-type supremum test and by testing the interaction between follow-up duration and the BP variables. In Cox models, including 2 BP indexes, we uncorrelated the BP levels by regressing one index on the other and by using the residual of one BP index and the measured level of the other. The residual of one BP index is the part of this BP index, which is unrelated to its counterpart on which it was regressed.^{10,11} We constructed heat maps to visualize the contribution of central and peripheral BP components to the associations with the end points.^{10,11} Improvement in the fit of nested Cox models was assessed by the log-likelihood ratio and the generalized R^2 statistic.¹² Statistical significance was a 2-tailed α -level of ≤ 0.05 .

Results

Baseline Characteristics of Participants

Of 6650 people qualifying for analysis, we excluded 1042 because they were younger than 30 years without end points (n=954), peripheral PP was > 130 mm Hg (n=10), central systolic BP was < 70 mm Hg (n=1) or > 230 mm Hg (n=1), central diastolic BP was > 150 mm Hg (n=1) or < 55 mm Hg (n=15), or because the pulse wave analysis was missing (n=60). This left 5608 participants for statistical analysis (Table 1). Missing values of body mass index (n=26), smoking (n=245), drinking (n=1069), serum creatinine (n=192), and blood glucose (n=161) were interpolated. Mean age was 54.2 years (Table 1). The study population included 3034 women (54.1%), 2388 (42.6%), 1823 (32.5%), and 1397 (24.9%) Europeans, Asians, and South Americans, 1179 smokers (21.0%), and 2818

Table 2. Correlation Matrix Between Central and Peripheral BP

BP	pSBP	pDBP	pPP	cSBP	cDBP	cPP	MAP
Correlations between measured peripheral and transfer-function derived central BP							
pSBP	...						
pDBP	0.64	...					
pPP	0.87	0.17	...				
cSBP	0.97	0.66	0.81	...			
cDBP	0.65	0.99	0.18	0.67	...		
cPP	0.84	0.20	0.95	0.86	0.20	...	
MAP	0.89	0.89	0.56	0.91	0.90	0.59	...
Correlations of residual BP with measured peripheral and transfer-function derived central BP							
rpSBP	0.23	-0.08	0.34	0.00	-0.08	0.06	-0.04
rpPP	0.15	-0.14	0.29	-0.07	-0.14	0.00	-0.10
rcSBP	0.00	0.23	-0.15	0.23	0.24	0.14	0.25
rcPP	0.10	0.21	0.00	0.32	0.21	0.29	0.28

MAP was peripheral diastolic BP plus one-third of pulse pressure (the difference between pSBP and pDBP). All correlation coefficients were significant ($P < 0.001$) except for the correlation coefficients between the residuals and the measured or transfer-function derived values of the counterpart. BP indicates blood pressure; cSBP/cDBP, central systolic/diastolic BP; MAP, mean arterial BP; pPP/cPP, peripheral/central pulse pressure; pSBP/pDBP, peripheral systolic/diastolic BP; rcSBP/rcPP, residuals derived by regressing cSBP/cPP on pSBP/pPP; and rpSBP/rpPP, residuals of pSBP/pPP derived by regressing pSBP/pPP on cSBP/cPP.

participants (50.3%) reporting alcohol consumption. Of 2987 participants (53.3%) with office hypertension, 1943 (65.0%) were taking antihypertensive drug treatment. The prevalence of diabetes mellitus and a history of cardiovascular disease was 338 participants (6.03%) and 792 (14.1%), respectively. Table S5 and Table S6 list the baseline characteristics of participants by fourths of the distribution of central and peripheral systolic BP. Risk factors, including male sex, the prevalence of hypertension, treated hypertension and renal dysfunction, age, body mass index, serum cholesterol, the total-to-HDL cholesterol ratio, and blood glucose consistently increased ($P < 0.001$) across categories of central (Table S5) and peripheral (Table S6) systolic BP.

Peripheral and Central BP

Systolic/diastolic BP and PP averaged 134.1/80.2 mm Hg and 53.9 mmHg peripherally and 123.7/81.2 mm Hg and 42.5 mmHg centrally (Table 1). MAP averaged 99.3 mmHg. On average, peripheral compared with central diastolic BP was 1.04 mmHg lower (95% CI, 1.02–1.06 mmHg; $P < 0.001$). Women had higher heart rate and central and peripheral PP, but lower peripheral systolic BP and lower central and peripheral diastolic BP than men had (Table S7). The central and peripheral BP levels were highly correlated (Table 2). Using the residual approach reduced the correlation coefficients between the corresponding peripheral and central BP indexes

from 0.97 for systolic BP and 0.95 for PP to association sizes, which were infinitesimally small (Table 2). The residual BP levels were correlated to their original BP indexes with correlation coefficients ranging from 0.23 to 0.29 and maintained their associations with sex (Table S7) and the continuous covariables, for which analyses were adjusted, that is, age, body mass index, the ratio of high to low-density cholesterol, and the estimated glomerular filtration rate (Table S8).

Absolute Risk Associated With Central and Peripheral BP

Median follow-up of 5608 participants amounted to 4.1 years (fifth–95th percentile interval, 2.2–12.1 years). Across cohorts (Table S1), median follow-up ranged from 2.3 years (fifth–95th percentile interval, 1.4–3.1 years) to 14.0 years (fifth–95th percentile interval, 8.5–14.4 years). During 31610 person-years of follow-up, the primary end point occurred in 255 participants (4.5%); 109 (1.9%) and 89 (1.6%) participants experienced a coronary end point or stroke, and 204 (3.6%) died. The corresponding rates expressed per 1000 person-years (95% CI) were 8.2 (95% CI, 7.2–9.2), 3.5 (95% CI, 2.8–4.1), 2.8 (95% CI, 2.2–3.4), and 6.5 (95% CI, 5.6–7.3), respectively.

Across increasing fourths of the central systolic BP distribution (Table S9), the primary end point occurred in 14 (1.0%), 36 (2.6%), 71 (5.1%), and 134 (9.6%) participants at




Figure 1. Cumulative incidence of the primary end point by fourths of the distributions of central systolic blood pressure (cSBP) and peripheral systolic blood pressure (pSBP). Tabulated data are the number of participants at risk at 5-y intervals. P values for trend were derived by Cox proportional hazards regression. Estimates accounted for sex and age (A and B). There were no differences in hazard ratios between cSBP (A) and pSBP (B; $P = 0.86$). Additional adjustment for pSBP (C) or cSBP (D) removed the significance.

rates per 1000 person-years of 3.9, 5.1, 9.0, and 16.6, respectively. Similarly, across fourths of the central PP distribution (Table S10), the primary end point occurred in 21 (1.5%), 34 (2.4%), 54 (3.9%), and 146 (10.4%) participants at rates of 4.1, 5.0, 7.3, and 22.0 per 1000 person-years. These rate trends were consistent for the secondary end points across the categories of the central systolic BP and PP (Table S9 and Table S10).

In all Cox models that follow, the proportional hazards assumption was met and the residual method, as described in the statistical methods, was applied if models included two BP components. The sex- and age-adjusted cumulative incidence of the primary end point derived by Cox regression ran higher across increasing categories of central and peripheral systolic BP and PP. There were no differences in hazard ratios between central and peripheral BP components ($P=0.86$ for systolic BP and $P=0.90$ for PP, Figure 1A and 1B and Figure S1A and S1B). Additional adjustment of these BP components for their counterpart weakened these associations to a nonsignificant level (Figure 1C and 1D and Figure S1C and

S1D). Findings for the cumulative incidence of the coronary end points (Figure S2) and stroke (Figure S3) in relation to systolic BP and PP were confirmatory.

Relative Risk Associated With the Central and Peripheral Pulsatile BP Components

In analyses adjusted for cohort, sex, age, body mass index, smoking and drinking status, the total-to-HDL serum cholesterol ratio, the estimated glomerular filtration rate, use of antihypertensive drugs, history of cardiovascular disease, and diabetes mellitus (Table 3), associations of the primary end point, total mortality, coronary end points, and stroke with systolic BP and PP were statistically significant ($P\leq 0.037$), irrespective of whether the pulsatile BP components were measured centrally or peripherally. The interaction terms between the pulsatile BP components and continent of recruitment were not significant in any model ($P\geq 0.18$).

Further adjustment of central for peripheral pulsatile BP, and vice versa, removed the significance of the associations of the primary end point, total mortality, coronary end points and

Table 3. Association of End Points With the Central and Peripheral Pulsatile BP Components

End Points (Number) BP Index*	Adjusted		Additionally Adjusted for cSBP or cPP*		Additionally Adjusted for pSBP or pPP*	
	HR (95% CI)†	P Value	HR (95% CI)‡	P Value	HR (95% CI)‡	P Value
Primary (255)						
cSBP	1.50 (1.33–1.70)	<0.001	...§	...§	1.01 (0.53–1.93)	0.97
cPP	1.36 (1.19–1.54)	<0.001	...§	...§	1.12 (0.67–1.89)	0.66
pSBP	1.49 (1.33–1.67)	<0.001	1.47 (0.79–2.74)	0.22	...§	...§
pPP	1.34 (1.19–1.51)	<0.001	1.20 (0.74–1.96)	0.47	...§	...§
Secondary						
Mortality (204)						
cSBP	1.16 (1.02–1.32)	0.025	...§	...§	0.63 (0.31–1.31)	0.22
cPP	1.18 (1.03–1.35)	0.017	...§	...§	0.77 (0.42–1.38)	0.37
pSBP	1.17 (1.04–1.33)	0.012	1.81 (0.90–3.65)	0.096	...§	...§
pPP	1.19 (1.05–1.36)	0.008	1.53 (0.87–2.66)	0.14	...§	...§
Coronary (109)						
cSBP	1.29 (1.05–1.58)	0.016	...§	...§	1.76 (0.64–4.84)	0.28
cPP	1.30 (1.05–1.60)	0.014	...§	...§	1.92 (0.85–4.33)	0.12
pSBP	1.25 (1.03–1.53)	0.028	0.74 (0.28–1.96)	0.47	...§	...§
pPP	1.23 (1.01–1.50)	0.037	0.68 (0.31–1.47)	0.33	...§	...§
Stroke (89)						
cSBP	1.65 (1.37–1.99)	<0.001	...§	...§	0.96 (0.32–2.88)	0.95
cPP	1.46 (1.19–1.79)	0.003	...§	...§	1.12 (0.46–2.70)	0.81
pSBP	1.64 (1.37–1.96)	<0.001	1.70 (0.59–4.89)	0.33	...§	...§
pPP	1.43 (1.18–1.74)	<0.001	1.30 (0.56–2.99)	0.81	...§	...§

BP indicates blood pressure; cPP, central pulse pressure; cSBP, central systolic BP; HDL, high-density lipoprotein; HR, hazard ratio; pPP, peripheral pulse pressure; and pSBP, peripheral systolic BP.

*pSBP/pPP, peripheral systolic blood pressure/pulse pressure; cSBP/cPP, central systolic blood pressure/pulse pressure.

†All HRs, given with 95% CI, expressed the relative risk associated with a 1-SD increment in BP and accounted for cohort, sex, age, body mass index, smoking and drinking, total-to-HDL serum cholesterol ratio, the estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.

‡HR were for the residual of the BP index.

§Not applicable.

stroke with both pulsatile BP components (Table 3). The log-likelihood ratios (Table 4) confirmed that adding a single pulsatile BP component to a base model including all covariables increased model fit ($P < 0.001$) with an increment in the generalized R^2 statistic ranging from 0.37% to 0.74%. However, adding a second pulsatile BP index to a model including already one pulsatile BP component along with covariables did not. Heat maps associating the primary end point with central and peripheral systolic BP or with central and peripheral PP (Figure 2) provided a graphical confirmation of these findings. Heat maps relating the secondary end points to central and peripheral systolic BP (Figure S4) or to central and peripheral PP (Figure S5) were confirmatory.

Sensitivity Analysis

Hazard ratios relating to the primary end point to the central and peripheral pulsatile BP components (Table S11) remained significant when additionally adjusted for diastolic BP ($P \leq 0.001$). Significance weakened when these hazard ratios were further adjusted for MAP ($0.026 \leq P \leq 0.32$) instead of diastolic BP. Sensitivity analyses of the primary end point in relation to central and peripheral pulsatile BP components in various subgroups (Table S12) delineated by treatment status, history of cardiovascular disease, or the presence of renal dysfunction at baseline confirmed the results reported in Table 3.

Discussion

The key point addressed by our study was whether the central pulsatile BP components, as exemplified by systolic BP or PP, provide statistically and clinically relevant improvement in risk stratification over and beyond their counterparts measured peripherally. The risk of the composite cardiovascular end point, total mortality, a coronary end point, and stroke increased with higher pulsatile BP, irrespective of whether pulsatile BP was measured centrally or peripherally. The strength of these associations was similar for central compared with peripheral pulsatile BP. The correlations close to unity ($P \geq 0.95$) between the central and peripheral pulsatile BP levels provided the explanation (Table 2). The underlying physiological explanation is that the radial pulse wave is recorded and calibrated on brachial BP, whereas the central waveform, from which central systolic BP and PP are derived, is extrapolated using a transfer function.⁸ Recalibration of the radial pulse wave on diastolic BP and MAP to reconstruct the aortic pulse wave did not weaken these correlations (Table S13). Adjustment of the central pulsatile BP for its peripheral counterpart and vice versa removed the significance of both central and peripheral pulsatile BP with gradients in the 5-year risks conferred across the BP scales (Figure 2). Furthermore, diastolic BP was similar centrally and peripherally (Table 1), and women had a higher heart rate and higher central and peripheral PP than men had (Table S7). These observations are in keeping with long-established hemodynamic principles¹³ and represent an internal validation of our study results.

Our current findings must be placed within the context of the abundant literature, suggesting that the association of adverse health outcomes with central systolic BP and central PP must be closer than with their peripheral counterparts.

Table 4. Fit of Cox Models Relating the Primary End point to Central and Peripheral Pulsatile Blood Pressure Components

Models	-2 Log L	χ^2 Statistic	P Value	R^2 (%) [*]
Base model†	3661.5			
+cSBP	3621.4	40.1	<0.001	0.713
+cPP	3641.0	20.5	<0.001	0.365
+pSBP	3620.0	41.5	<0.001	0.737
+pPP	3640.7	20.9	<0.001	0.371
Base model including pSBP‡	3620.0			
+cSBP	3620.0	0.004	0.95	<0.001
Base model including pPP‡	3640.7			
+cPP	3640.5	0.18	0.67	0.003
Base model including cSBP§	3621.4			
+pSBP	3620.0	1.35	0.24	0.024
Base model including cPP§	3641.0			
+pPP	3640.5	0.52	0.47	0.009

cPP indicates central pulse pressure; cSBP, central systolic BP; HDL, high-density lipoprotein; pPP, peripheral pulse pressure; and pSBP, peripheral systolic BP.

^{*} R^2 is an estimate of the additional variance explained (https://apha.confex.com/apha/134am/techprogram/paper_135906.htm).

†Included cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking, total-to-HDL cholesterol ratio, estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.

‡Base model, including pSBP or pPP, respectively, extended by cSBP or cPP.

§Base model, including cSBP or cPP, respectively, extended by pSBP or pPP.

However, approximately half of the published studies had a cross-sectional design with preclinical outcomes.¹⁴⁻¹⁹ The longitudinal studies related a broad spectrum of outcomes with central BP, but applied different technologies to quantify the risk marker and not always accounted for peripheral BP.^{16,17,20-25} Other factors limiting the interpretation of the available literature are a sample size of <200 ,^{14,15,26,27} a follow-up confined to 1 year or less,²⁰ selective enrollment of patients with hypertension,^{14,19,22,26,28} renal dysfunction^{15,18,29} or coronary heart disease.²⁰ In a meta-analysis of summary statistics extracted from 11 studies that included 5648 patients followed up for 3.8 years, central PP was only associated with a marginally higher relative risk of clinical end points ($P=0.057$).³⁰ Most patients were either elderly or had coronary arterial or end-stage renal disease.³⁰ In the Conduit Artery Function Evaluation Study,²² the multivariable-adjusted hazard ratios relating peripheral and central PP to the composite cardiovascular end point were similar (1.10 [$P=0.050$] versus 1.11 [$P=0.048$]), again confirming our current findings, but in the setting of a randomized controlled trial.

Strengths and Limitations

From the perspective of generalizability, participants were enrolled in 9 countries and 3 continents. End points encompassed both fatal and nonfatal events, which were all validated against the source documents available in each country. Notwithstanding these strengths, our study has limitations.




Figure 2. Heat maps depicting the 5-year risk of the primary end point in relation to central and peripheral systolic blood pressure (SBP) or pulse pressure (PP) in 5608 study participants. Heat maps were derived by Cox proportional hazard regression. Risk estimates were standardized to the average of the distributions in the whole study population (mean or ratio) of cohort identifier, sex, age, body mass index, smoking and drinking, the total-to-HDL (high-density lipoprotein) serum cholesterol ratio, the estimated glomerular filtration rate, intake of antihypertensive drug, history of cardiovascular disease, and diabetes mellitus. Numbers in grids **A** and **C** represent the percent of participants within each cross-classification category of central and peripheral SBP or PP. Numbers in grids **B** and **D** represent the 5-year risk of a primary end point.

First, we had no information on blacks of African descent or blacks born and living in Africa, who are more susceptible to the complications of hypertension than other ethnic groups. Second, the tonometric reconstruction of the aortic pulse wave from the radial pulse wave requires the application of a generalized transfer function, which has been criticized.³¹ However, the tonometric approach, as applied in our current study, has been invasively validated.⁸ Third, the tonometric method requires a 2-point calibration, either on peripheral systolic and diastolic BP or on peripheral diastolic BP and MAP. Whatever calibration was applied, the correlations between the central and peripheral systolic BP components were equally high (Table 2 and Table S13). In calculating peripheral MAP from systolic and diastolic BP, a form factor of 33 or 40 can be applied.³² Whether MAP is computed using form factor 33 or 40 does not matter in Cox regression (data not shown). Indeed, the difference in calibration on MAP form factor 33 versus 40 involves a constant factor in each individual participant, that is, 7% of PP. This constant will not affect the significance of hazard ratios; if expressed per 1-SD increment in the pulsatile BP, hazard ratios will also be similar. Fourth, the rates of coronary revascularization, a component of the primary and coronary end points differed across cohorts, based on sample size and the age distribution: 2.31% (N=27/1171) in Noordkempen, Belgium; 0.05% (N=1/1823) in JingNing, China; 2.75% (N=35/1271) in Buenos Aires, Argentina; and 2.30% (N=10/435) in Finland. However, analyses were

adjusted for cohort as a random effect. Finally, confounding factors, such as antihypertensive treatment, smoking and drinking status, or renal dysfunction, were only assessed at baseline so that they could not be accounted for in a time-dependent manner.

Perspectives

In a large population-based cohort, the strength of the associations of the primary and secondary end points with the central BP components was not stronger than with their peripheral counterparts. Thus, the concept that central systolic BP and central PP would refine risk stratification over and beyond peripheral systolic BP or peripheral PP could not be confirmed. In other words, a carefully recorded peripheral systolic BP or PP is accurate in risk stratification without need of measuring their central counterparts in adults aged ≥30 years. Our current analysis is relevant for clinical medicine but has no bearing on the key role of studying central hemodynamic measurements as a way to gain deeper insight into the pathophysiology of cardiovascular disease.

Appendix

IDCARS Investigators

Argentina, Buenos Aires: LS Aparicio, J Barochiner; Belgium, Noordkempen: L Thijs, JA Staessen, FF Wei, WY Yang, ZY Zhang; China, JingNing: YB Cheng, QH Guo, JF Huang, QF Huang, Y

Li, CS Sheng, JG Wang; Czech Republic, Pilsen: J Filipovský, J Seidlerová; Finland, FINRISK: EP Juhanoja, AM Jula, AS Lindroos, TJ Niiranen, SS Sivén; Italy, Padova: E Casiglia, A Pizzoli, V Tikhonoff; Nigeria, Abuja: BS Chori, B Danladi, AN Odili, H Oshaju; Poland, Gdańsk: W Kucharska, K Kunicka, N Gilis-Malinowska, K Narkiewicz, W Sakiewicz, E Swierblewska; Poland, Kraków: K Kawecka-Jaszcz, K Stolarz-Skrzypek; South Africa, Potchefstroom: AE Schutte; South Africa, Johannesburg: GR Norton, AJ Woodiwiss; Switzerland, Bern, Geneva and Lausanne: D Ackermann, M Bochud, B Ponte, M Pruijm; Uruguay, Montevideo: R Álvarez-Vaz, C Américo, C Baccino, L Borgarello, L Florio, P Moliterno, A Noboa, O Noboa, A Olascoaga, P Pamizari, M Pécora.

Disclosures

None.

Sources of Funding

Supported by Argentina: The Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Belgium: European Union (HEALTH-F7-305507 HOMAGE), European Research Council (Advanced Researcher Grant 2011-294713-EPLORE and Proof-of-Concept Grant 713601-uPROPHET), European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT) and Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium (G.0881.13); China: The National Natural Science Foundation of China (grants 81470533, 81400312, 81770455, 81970353, and 91639203), the Ministry of Science and Technology (2016YFC0900902, 2016YFC1300100 and 2018YFC1704902), Beijing, China, and by the Shanghai Commissions of Science and Technology (grants 19ZR1443300, 14ZR1436200 and 15XD1503200), and the Shanghai Municipal Health Commission (15GWZK0802, 2017BR025, 201940297 and a Grant for Leading Academics); Czech Republic: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) and Charles University Research Fund (project P36); Finland: Academy of Finland (grant 321351), Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Urmas Pekkala Foundation, and the Hospital District of South-Western Finland; Italy: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550); Poland (Gdańsk): European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550); Poland (Kraków): European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) and Foundation for Polish Science; Uruguay: Asociación Española Primera en Salud; and Switzerland: Swiss National Science Foundation (FN 33CM30-124087 and FN 33CM30-140331). The NPA Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium received a nonbinding grant from OMRON Healthcare, Co, Ltd, Kyoto, Japan.

References

- Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, Naghavi M, Salomon JA, Shibuya K, Vos T, et al. GBD 2010: design, definitions, and metrics. *Lancet*. 2012;380:2063–2066. doi: 10.1016/S0140-6736(12)61899-6
- O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. *Hypertension*. 2005;46:200–204. doi: 10.1161/01.HYP.0000168052.00426.65
- Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekblom T, Gueyffier F, Liu L, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet*. 2000;355:865–872. doi: 10.1016/S0140-6736(99)07330-4
- Mitchell GF, Wang N, Palmisano JN, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS. Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. *Circulation*. 2010;122:1379–1386. doi: 10.1161/CIRCULATIONAHA.109.914507
- Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Cheng S, Aragam J, Levy D, Benjamin EJ, Vasan RS, et al. Relations of central hemodynamics and aortic stiffness with left ventricular structure and function: the framingham heart study. *J Am Heart Assoc*. 2016;5:e002693. doi: 10.1161/JAHA.115.002693
- Vasan RS, Short MI, Niiranen TJ, Xanthakis V, DeCarli C, Cheng S, Seshadri S, Mitchell GF. Interrelations between arterial stiffness, target organ damage, and cardiovascular disease outcomes. *J Am Heart Assoc*. 2019;8:e012141. doi: 10.1161/JAHA.119.012141
- McEnery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. *Eur Heart J*. 2014;35:1719–1725. doi: 10.1093/eurheartj/ehs565
- Paucal AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. *Hypertension*. 2001;38:932–937. doi: 10.1161/hy1001.096106
- World Health Organization. *Global Status Report on Alcohol and Health 2018*. Geneva, Switzerland: World Health Organization; 2018.
- Pencina MJ, D'Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD, Peterson ED, Vasan RS, Sniderman AD. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. *Eur J Prev Cardiol*. 2015;22:1321–1327. doi: 10.1177/2047487315569411
- Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, et al; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. *JAMA*. 2019;322:409–420. doi: 10.1001/jama.2019.9811
- Gillespie BW. Use of generalized R-squared in Cox regression APHA Scientific Session and Event Listing 2006. Available at: http://apha.confex.com/apha/134am/techprogram/paper_135906.htm.
- Gu YM, Thijs L, Li Y, Asayama K, Boggia J, Hansen TW, Liu YP, Ohkubo T, Björklund-Bodegård K, Jeppesen J, et al; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. *Hypertension*. 2014;63:229–237. doi: 10.1161/HYPERTENSIONAHA.113.02179
- Boutouyrie P, Bussy C, Lacombe P, Gierd X, Laloux B, Laurent S. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. *Circulation*. 1999;100:1387–1393. doi: 10.1161/01.cir.100.13.1387
- Covic A, Goldsmith DJ, Panaghiu L, Covic M, Sedor J. Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. *Kidney Int*. 2000;57:2634–2643. doi: 10.1046/j.1523-1755.2000.00124.x
- Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. *Hypertension*. 2007;50:197–203. doi: 10.1161/HYPERTENSIONAHA.107.089078
- Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? *J Hypertens*. 2009;27:461–467. doi: 10.1097/hjh.0b013e32823220ea4
- DeLoach SS, Appel LJ, Chen J, Joffe MM, Gadegebeku CA, Mohler ER III, Parsa A, Perumal K, Rafey MA, Steigerwalt SP, et al. Aortic pulse pressure is associated with carotid IMT in chronic kidney disease: report from Chronic Renal Insufficiency Cohort. *Am J Hypertens*. 2009;22:1235–1241. doi: 10.1038/ajh.2009.156
- Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, McG Thom SA, Hughes AD; Anglo-Scandinavian Cardiac Outcome Trial Investigators. Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. *Hypertension*. 2009;54:724–730. doi: 10.1161/HYPERTENSIONAHA.108.125740
- Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K, Hayashi T. Pulsatility of ascending aortic pressure waveform is a powerful predictor of restenosis after percutaneous transluminal coronary angioplasty. *Circulation*. 2000;101:470–472. doi: 10.1161/01.cir.101.5.470
- Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation*. 2006;113:664–670. doi: 10.1161/CIRCULATIONAHA.105.579342
- Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function

- Evaluation (CAFE) study. *Circulation*. 2006;113:1213–1225. doi: 10.1161/CIRCULATIONAHA.105.595496
23. Jankowski P, Kawecka-Jaszcz K, Czarnicka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badelek M, Wiliński J, Curyło AM, Dudek D; Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. *Hypertension*. 2008;51:848–855. doi: 10.1161/HYPERTENSIONAHA.107.101725
 24. Redelinghuys M, Norton GR, Scott L, Maseko MJ, Brooksbank R, Majane OH, Sareli P, Woodiwiss AJ. Relationship between urinary salt excretion and pulse pressure and central aortic hemodynamics independent of steady state pressure in the general population. *Hypertension*. 2010;56:584–590. doi: 10.1161/HYPERTENSIONAHA.110.156323
 25. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation*. 2010;121:505–511. doi: 10.1161/CIRCULATIONAHA.109.886655
 26. Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B, Brunner H, Laurent S. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. *Circulation*. 2000;101:2601–2606. doi: 10.1161/01.cir.101.22.2601
 27. Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, Masotti G, Roman MJ. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARE Dicomano Study. *J Am Coll Cardiol*. 2008;51:2432–2439. doi: 10.1016/j.jacc.2008.03.031
 28. Dart AM, Gatzka CD, Kingwell BA, Willson K, Cameron JD, Liang YL, Berry KL, Wing LM, Reid CM, Ryan P, et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. *Hypertension*. 2006;47:785–790. doi: 10.1161/01.HYP.0000209340.33592.50
 29. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, London GM. Central pulse pressure and mortality in end-stage renal disease. *Hypertension*. 2002;39:735–738. doi: 10.1161/hy0202.098325
 30. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;55:1318–1327. doi: 10.1016/j.jacc.2009.10.061
 31. Segers P, Mahieu D, Kips J, Van Bortel LM. The use of a generalized transfer function: different processing, different results! *J Hypertens*. 2007;25:1783–1787. doi: 10.1097/HJH.0b013e3282ef5c5f
 32. Bos WJ, Verrij E, Vincent HH, Westerhof BE, Parati G, van Montfrans GA. How to assess mean blood pressure properly at the brachial artery level. *J Hypertens*. 2007;25:751–755. doi: 10.1097/HJH.0b013e32803fb621

Novelty and Significance

What Is New?

- In a population-based cohort of people aged ≥ 30 years, the risk of a composite cardiovascular end point, total mortality, a coronary end point and stroke increased with higher systolic blood pressure and pulse pressure, irrespective of whether these pulsatile blood pressure components were measured centrally or peripherally. Our study showed that central systolic blood pressure and pulse pressure did not improve risk stratification over and beyond their peripheral counterparts.
- Correlations close to unity between the central and peripheral pulsatile blood pressure levels provided the explanation.

What Is Relevant?

- A carefully recorded peripheral pulsatile blood pressure component is sufficient in risk stratification without the need of measuring their

central counterparts to refine risk prediction in adults older than 30 years.

- Our observations are relevant for clinical medicine, but have no bearing on the key role of studying central hemodynamic measurements as a way to gain deeper insight in the pathophysiology of cardiovascular disease.

Summary

Associations of cardiovascular complications with systolic blood pressure and pulse pressure were not stronger if blood pressure was measured centrally, compared with peripherally. The emphasis in daily clinical practice should remain on the careful measurement of brachial blood pressure.

Data Supplement

Cardiovascular Endpoints and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components

QF Huang, LS Aparicio, L Thijs, FF Wei, JD Melgarejo, YB Cheng, CS Sheng, WY Yang, N Gilis-Malinowska, J Boggia, TJ Niiranen, W Wojciechowska, K Stolarz-Skrzypek, J Barochiner, D Ackermann, V Tikhonoff, B Ponte, M Pruijm, E Casiglia, K Narkiewicz, J Filipovský, D Czamecka, K Kawecka-Jaszcz, AM Jula, M Bochud, T Vanassche, P Verhamme, HAJ Struijker-Boudier, JG Wang, ZY Zhang, Y Li, JA Staessen, and the International Database of Central Arterial Properties for Risk Stratification Investigators

Table of Contents	Page
References	S3
Table S1. Baseline and follow-up by cohort	S5
Table S2. Literature sources by cohort	S6
Table S3. Assessment of central haemodynamics by cohort	S7
Table S4. ICD coding and number of endpoints in 5608 participants	S8
Table S5. Baseline characteristics of participants by fourths of the distribution of central systolic BP	S9
Table S6. Baseline characteristics of participants by fourths of the distribution of peripheral systolic BP	S10
Table S7. Hemodynamic measurements in 3034 women and 2574 men	S11
Table S8. Correlation matrix of BP with clinical and biochemical variables	S12
Table S9. Incidence of endpoints by fourths of the distributions of central and peripheral systolic BP	S13
Table S10. Incidence of endpoints by fourths of the distributions of central and peripheral pulse pressure	S14
Table S11. Association of the primary endpoint with the pulsatile and steady BP components	S15
Table S12. Association of the primary endpoint with the central and peripheral pulsatile BP components in various subgroups	S16
Table S13. Correlation matrix between peripheral and central BP levels using peripheral diastolic and mean arterial BP for calibration	S17
Figure S1. Cumulative incidence of the primary endpoint by fourths of the distributions of central and peripheral pulse pressure	S18
Figure S2. Cumulative incidence of the secondary endpoints by fourths of the distributions of central systolic BP.	S19
Figure S3. Cumulative incidence of the secondary endpoints by fourths of the distributions of central pulse pressure.	S20
Figure S4. Heat maps depicting the 5-year risk of secondary endpoints in relation to central and peripheral SBP	S21
Figure S5. Heat maps depicting the 5-year risk of secondary endpoints in relation to central and peripheral PP	S22

References

1. Cuffaro P, Morales M, Barochiner J, Rada M, Alfie J, Aparicio L, Galarza C, Micali R, Marin M, Waisman G. Validation of a new piezoelectric device for noninvasive measurement of central aortic systolic blood pressure. *Blood Press Monit.* 2018;23:49–51.
2. Aparicio LS, Barochiner J, Peuchot VA, Giunta DH, Martínez R, Morales MS, Cuffaro PE, Waisman GD. Comparing office, central, home and ambulatory blood pressure in predicting left ventricular mass. *Hipertens Riesgo Vasc.* 2019;36:5–13.
3. Jin Y, Kuznetsova T, Maillard M, Richter T, Thijs L, Bochud M, Herregods MC, Burnier M, Fagard R, Staessen JA. Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. *Hypertension.* 2009;54:489–495.
4. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, Jin Y, Olszanecka A, Maljutina S, Casiglia E, Filipovsky J, Kawecka-Jaszcz K, Nikitin Y, Staessen JA, European Project On Genes in Hypertension (EPOGH) Investigators. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. *J Am Med Ass.* 2011;305:1777–1785.
5. Wei FF, Trenson S, Monney P, Yang WY, Pruijm M, Zhang ZY, Bouatou Y, Huang QF, Ponte B, Martin PY, Thijs L, Kuznetsova T, Allegaert K, Janssens S, Vermeer C, Verhamme P, Burnier M, Bochud M, Ehret G, Staessen JA. Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. *PLoS One.* 2018;13:e0193967.
6. Liu YP, Thijs L, Kuznetsova T, Gu YM, Asayama K, Stolarz-Skrzypek K, Jin Y, Verhamme P, Struijker-Boudier HAJ, Staessen JA. Central systolic augmentation indexes and urinary sodium in a white population. *Am J Hypertens.* 2013;26:95–103.
7. Liu YP, Gu YM, Thijs L, Asayama K, Jin Y, Jacobs L, Kuznetsova T, Verhamme P, Van Bortel L, Struijker-Boudier H, Staessen JA. Do level and variability of systolic blood pressure predict arterial properties or vice versa? *J Hum Hypertens.* 2013;28:316–322.
8. Li Y, Wang JG, Nawrot T, Wang GL, Qian YS, Staessen JA, Zhu DL. Are published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The JingNing population study. *Blood Press Monit.* 2005;10:125–134.
9. Li Y, Staessen JA, Li LH, Gao PJ, Thijs L, Brand E, Brand-Herrmann SM, Zhu DL, Wang JG. Blood pressure and urinary sodium excretion in relation to the A-1984G adrenomedullin polymorphism in a Chinese population. *Kidney Intern.* 2006;69:1153–1158.
10. Li Y, Wang JG, Gao PJ, Wang GL, Qian YS, Zhu DL, Staessen JA. Interaction between body mass index and alcohol intake in relation to blood pressure in HAN and SHE Chinese. *Am J Hypertens.* 2006;19:448–453.
11. Li Y, Staessen JA, Sheng CS, Huang QF, O'Rourke M, Wang JG. Age dependency of peripheral and central systolic pressures : cross-sectional and longitudinal observations in a Chinese population. *Hypertens Res.* 2012;35:115–122.
12. Li Y, Staessen JA, Li LH, Huang QF, Lu L, Wang JG. Reference values for the arterial pulse wave in Chinese. *Am J Hypertens.* 2008;21:668–673.
13. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K, Babeanu S, Casiglia E, Filipovsky J, Nachev C, Nikitin Y, Peleskã J, O'Brien E. Quality control of the blood pressure phenotype in the European Project on Genes in hypertension. *Blood Press Monit.* 2002;7:215–224.
14. Wojciechowska W, Staessen JA, Nawrot T, Cwynar M, Sleidlerová J, Stolarz K, Gasowski J, Tichá M, Richart T, Thijs L, Grodzicki T, Kawecka-Jaszcz K, Filipovský J, on behalf of the European Project on Genes in Hypertension. Reference values in White

- Europeans for the arterial pulse wave recorded by means of the ShyymoCor device. *Hypertens Res.* 2006;29:475–483.
15. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol.* 2010;39:504–518.
 16. Johansson JK, Puukka PJ, Jula AM. Interarm blood pressure difference and target organ damage in the general population. *J Hypertens.* 2014;32:260–266.
 17. Świerblewska E, Wolf J, Kunicka K, Graff B, Polonis K, Hoffmann M, Chrostowska M, Szyndler A, Bandosz P, Graff B, Narkiewicz K. Prevalence and distribution of left ventricular diastolic dysfunction in treated patients with long-lasting hypertension. *Blood Press.* 2018;27:376–384.
 18. Polonis K, Hoffmann M, Szyndler A, Wolf J, Nowak R, Becari C, Laurent S, Boutouyrie P, Melander O, Narkiewicz K. A multilocus genetic risk score is associated with arterial stiffness in hypertensive patients: the CARE NORTH study. *J Hypertens.* 2018;36:1882–1888.
 19. Luzardo L, Lujambio I, Sottolano M, da Rosa A, Robaina S, Arce F, Márquez M, Agorrody V, Américo C, Garau M, Krul N, Ríos AC, Florio L, Olascoaga A, Naboia O, Staessen JA, Boggia J. Cohorte GEFA-HT-UY (GEnotipo, Fenotipo y Ambiente de la HiperTensión arterial en Uruguay). Protocolo and primeros resultados. *Rev Méd Urug.* 2013;29:103–113.
 20. Luzardo L, Sottolano M, Lujambio I, Robaina S, Thijs L, da Rosa A, Krul N, Carusso F, Ríos AC, Olascoaga A, Naboia O, Staessen JA, Boggia J. Quality of the blood pressure phenotype in the GEnotipo, Fenotipo y Ambiente de la hipertensión arterial en Uruguay (GEFA-HT-UY) study. *Blood Press Monit.* 2014;19:339-345.
 21. Lujambio I, Sottolano M, Luzardo L, Robaina S, Krul N, Thijs L, Carusso F, da Rosa A, Ríos AC, Olascoaga A, Garau M, Gadola L, Naboia O, Staessen JA, Boggia J. Estimation of glomerular filtration rate based on serum cystatin c vs. creatinine in a Uruguayan population. *Int J Nephrol.* 2014;2014:837106.
 22. Luzardo L, Lujambio I, Sottolano M, da Rosa A, Thijs L, Naboia O, Staessen JA, Boggia J. 24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation : a feasibility study. *Hypertens Res.* 2012;35:980–987.
 23. Boggia J, Luzardo L, Lujambio I, Sottolano M, Robaina S, Thijs L, Olascoaga A, Naboia O, Struijker-Boudier HA, Safar ME, Staessen JA. The diurnal profile of central hemodynamics in a general Uruguayan population. *Am J Hypertens.* 2016;29:737–746.

Table S1. Baseline and Follow-Up by Cohort

Catchment Area	Baseline			Vascular Examination (years)	N° of Participants		Follow-Up	
	Sampling Frame	Sampling Method	IPR (%)		In Database	Analyzed	Last (year)	Median in Years (5–95% Interval)
Argentina, Buenos Aires	NA	Out-patient clinic	NA	2011–2015	1428	1271	2018	3.3 (1.2–4.5)
Belgium, Noordkempen	Family-based random sample	Address list	78	2005–2015	1365	1171	2018	8.9 (3.3–12.3)
China, Zhejiang, JingNing	Family-based random sample	All villagers invited	62	2003–2008	2069	1823	2012	4.0 (3.6–7.6)
Czech Republic, Pilsen	Family-based random sample	Address list	82	2000–2006	206	123	2015	14.0 (8.5–14.4)
Finland, Finrisk	Community-based random sample	Population registry	70	2007	488	435	2014	6.9 (6.8–6.9)
Italy, Padova	Family-based random sample	Address list	73	2006–2008	302	252	2013	6.6 (5.9–7.2)
Poland, Gdańsk	Hypertensive patients	Out-patient clinic	90	2008–2010	297	188	2017	6.1 (4.8–8.6)
Poland, Kraków, Niepolomice	Family-based random sample	Address list	54	2001–2008	391	219	2014	12.0 (6.1–12.2)
Uruguay, Montevideo	Age-stratified random sample	Members of a health insurance organization	78	2013–2016	325	126	2016	2.3 (1.4–3.1)

Abbreviation: IPR, initial participation rate. The European Project on Genes in Hypertension included participants recruited in Kraków, Pilsen and Padova. Participants from Padova were recruited in Mirano in the province of Venice and in Torrebelticino and Valli del Pasubio in the province of Vicenza. Sample size refers to the number of participants, who underwent an assessment of central hemodynamics at least once. NA indicates not applicable. The timing of the vascular examination is baseline for the longitudinal analyses in the current manuscript.

Table S2. Literature Sources by Study

Study Identification		Literature Sources	
Location	Name	Design	Hemodynamics
Argentina, Buenos Aires	Hospital Italiano de Buenos Aires	NA	1 2
Belgium, Noordkempen	Flemish Study on Environment Genes and Health Outcomes (FLEMENGHO)	3 4 5	6 7
China, Zhejiang, JingNing	JingNing Population Study (JNPS)	8 9 10	11 12
Czech Republic, Pilsen	European Project on Genes in Hypertension (EPOGH)	4 13	14
Finland, Finrisk	Finrisk	15	16
Italy, Padova	European Project on Genes in Hypertension (EPOGH)	4 13	14
Poland, Gdańsk	CARE NORTH	17	18
Poland, Kraków, Niepolomice	European Project on Genes in Hypertension (EPOGH)	4 13	14
Uruguay, Montevideo	Genotipo, Fenotipo y Ambiente de la Hipertensión Arterial en Uruguay (GEFA-HT-UY)	19 20 21	22 23

References are listed on pages S3-S4. NA indicates not available.

Table S3. Assessment of Central Hemodynamics by Cohort

Study	SphygmoCor Device		Blood Pressure Measurement Performed for Calibration		
	Type	Software	Monitor	Supine Rest (minutes)	No of Readings
Argentina, Buenos Aires	CvMS	9.0	Omron 705 CP	5	1-3
Belgium, Noordkempen	CvMS	7.1	Omron 705 CP	15	2
China, Zhejiang, JingNing	CvMS	6.3, 7.1	Omron 705 CP	5	3
Czech Republic, Pilsen	CvMS	7.1	Omron 705 CP	15	2
Finland, Finrisk	CvMS	7.1	Omron M6	5	3
Italy, Padova	CvMS	7.1	Omron 705 CP	15	2
Poland, Gdańsk	CvMS	7.1	Mercury sphygmomanometer	5	1
Poland, Kraków, Niepolomice	CvMS	7.1	Omron 705 CP	15	2
Uruguay, Montevideo	CvMS	8.2	Omron 714, 7220	15	1

Software refers to the version used for data acquisition.

Table S4. ICD Coding and Number of Endpoints in 5608 Participants

Endpoint	ICD Codes by Version			Number of Endpoints		
	8	9	10	All	Fatal	Nonfatal
Total mortality				204	204	
Cardiovascular mortality	390-458, 519.1, 782.4, 795	390-459	I00-I79, J81, R96	59	59	
Noncardiovascular mortality				102	102	
Fatal renal failure				3	3	
Cause unknown	799	798.9, 799	R98, R99	40	40	
Cardiovascular endpoints				317		
Coronary endpoints				132	24	108
Death from ischemic heart disease	410-412, 414	410-412, 414	I20, I24-I25	8	8	
Sudden death	795	798.1, 798.2, 798.9	I46, R96	7	7	
Myocardial infarction	410	410	I21-I22	41	4	37
Coronary revascularization	73	3	70
Heart failure	427.0, 427.1, 428, 429, 519.1, 782.4	428 (429.4) ^a	I50, I11.0, I13.0, I13.2, J81	61	11	50
Stroke	430-434, 436, fatal 438	430-434, 436	I60-I64, fatal I65-I68	89	26	63

Median follow-up was 4.1 years (5th-95th percentile interval, 2.2-12.1 years). Nonfatal events do not add up, because within each category only the first event was analyzed.

^a Code 429.4 was only applied in the Uruguayan cohort.

Table S5. Baseline Characteristics of Participants by Fourths of the Distribution of Central Systolic BP

Characteristic	Categories of Central Systolic BP (mm Hg)				<i>p</i> ^a
	<109 N=1402	109-119 N=1402	120-135 N=1402	≥136 N=1402	
Number (%) with characteristic					
Men	620 (44.2)	723 (51.6)	659 (47.0)	572 (40.8)	0.013
Current smoking ^b	367 (26.2)	323 (23.0)	237 (16.9)	252 (18.0)	<0.001
Drinking alcohol ^b	704 (50.2)	755 (53.9)	703 (50.1)	656 (46.8)	0.68
Office hypertension ^c	174 (12.4)	470 (33.5)	942 (67.2)	1401 (99.9)	<0.001
On antihypertensive treatment ^b	178 (12.7)	412 (29.4)	610 (43.5)	743 (53.0)	<0.001
Diabetes mellitus ^b	44 (3.14)	68 (4.85)	107 (7.63)	119 (8.49)	<0.001
History of cardiovascular disease ^b	87 (6.2)	144 (10.3)	239 (17.1)	322 (23.0)	<0.001
Renal dysfunction ^d	84 (6.0)	117 (8.4)	186 (13.3)	313 (22.3)	<0.001
Mean (±SD) of characteristic					
Age (year)	44.4±11.5	51.5±12.9	57.5±13.3	63.4±12.5	<0.001
Body mass index (kg/m ²)	24.2±4.2	26.0±4.8	27.1±5.1	26.1±4.8	<0.001
Biochemistry ^e					
Serum total cholesterol (mg/dL)	186.6±37.4	196.1±38.7	199.1±38.4	199.9±39.7	<0.001
Serum HDL cholesterol (mg/dL)	57.8±14.4	56.7±15.2	56.3±14.5	59.2±16.5	0.025
Total-to-HDL cholesterol ratio	3.42±1.09	3.66±1.09	3.74±1.11	3.59±1.13	<0.001
Serum non-HDL cholesterol (mg/dL)	128.8±38.0	139.4±38.6	142.8±38.5	140.7±40.2	<0.001
Serum creatinine (mg/dL)	0.92±0.22	0.93±0.25	0.93±0.25	0.96±0.38	0.002
Glomerular filtration (mL/min/1.73 m ²) ^d	88.2±18.8	85.0±18.7	81.2±19.1	75.6±19.6	<0.001
Blood glucose, mg/dL	85.6±16.3	90.0±18.2	93.5±19.4	93.7±21.3	<0.001

^a Significance of linear trend across BP categories.

^b Assessed by questionnaire at baseline. Current smoking was inhaling tobacco smoke on a daily basis. Drinking alcohol was the occasional or daily consumption of ethanol containing beverages. Diabetes was use of antidiabetic drugs, fasting blood glucose of ≥126 mg/dL, random blood glucose of ≥200 mg/dL, a self-reported diagnosis, or diabetes documented in practice or hospital records.

^c Hypertension was a peripheral BP of ≥140 mm Hg systolic or ≥90 mm Hg diastolic, or use of antihypertensive drugs.

^d The glomerular filtration rate was derived from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration formula. Renal dysfunction was a glomerular filtration rate <60 mL/min/1.73 m².

^e Measured at baseline by automated enzymatic methods in certified laboratories.

Table S6. Baseline Characteristics of Participants by Fourths of the Distribution of Peripheral Systolic BP

Characteristic	Categories of Peripheral Systolic BP (mm Hg)				<i>p</i> ^a
	<120 N=1402	120-130 N=1402	131-145 N=1402	≥146 N=1402	
Number (%) with characteristic					
Men	511 (36.5)	722 (51.5)	707 (50.4)	634 (45.2)	<0.001
Current smoking ^b	358 (25.5)	320 (22.8)	243 (17.3)	258 (18.4)	<0.001
Drinking alcohol ^b	691 (49.3)	727 (51.9)	734 (52.4)	666 (47.5)	0.06
Office hypertension ^c	209 (14.9)	427 (30.5)	949 (67.7)	1402 (100)	<0.001
On antihypertensive treatment ^b	213 (15.2)	381 (27.2)	585 (41.7)	764 (54.5)	<0.001
Diabetes mellitus ^b	41 (2.92)	61 (4.35)	103 (7.35)	133 (9.49)	<0.001
History of cardiovascular disease ^b	94 (6.7)	146 (10.4)	230 (16.4)	322 (23.0)	<0.001
Renal dysfunction ^d	97 (6.9)	112 (8.0)	184 (13.1)	307 (21.9)	<0.001
Mean (±SD) of characteristic					
Age (year)	46.8±12.0	50.9±13.0	56.3±14.2	62.9±13.1	<0.001
Body mass index (kg/m ²)	24.3±4.3	25.9±4.7	26.8±5.0	26.3±4.9	<0.001
Biochemistry ^e					
Serum total cholesterol (mg/dL)	189.1±38.0	195.3±39.2	197.9±37.7	199.5±40.0	<0.001
Serum HDL cholesterol (mg/dL)	58.4±14.4	56.7±15.1	56.3±14.6	58.5±16.6	0.88
Total-to-HDL cholesterol ratio	3.41±1.05	3.66±1.14	3.71±1.08	3.63±1.14	<0.001
Serum non-HDL cholesterol (mg/dL)	130.6±38.3	138.6±39.6	141.5±37.6	141.0±40.4	<0.001
Serum creatinine (mg/dL)	0.91±0.21	0.92±0.23	0.94±0.27	0.97±0.39	<0.001
Glomerular filtration (mL/min/1.73 m ²) ^d	86.6±18.2	85.7±19.1	81.7±19.3	76.0±20.1	<0.001
Blood glucose, mg/dL	85.9±15.4	89.5±18.4	92.9±19.6	94.5±21.7	<0.001

^a Significance of linear trend across BP categories.

^b Assessed by questionnaire at baseline. Current smoking was inhaling tobacco smoke on a daily basis. Drinking alcohol was the occasional or daily consumption of ethanol containing beverages. Diabetes was use of antidiabetic drugs, fasting blood glucose of ≥126 mg/dL, random blood glucose of ≥200 mg/dL, a self-reported diagnosis, or diabetes documented in practice or hospital records.

^c Hypertension was a peripheral BP of ≥140 mm Hg systolic or ≥90 mm Hg diastolic, or use of antihypertensive drugs.

^d The glomerular filtration rate was derived from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration formula. Renal dysfunction was a glomerular filtration rate <60 mL/min/1.73 m².

^e Measured at baseline by automated enzymatic methods in certified laboratories.

Table S7. Hemodynamic Measurements in 3034 Women and 2574 Men

Hemodynamic Variable	Women	Men	Δ	
			Δ (95% CI)	<i>P</i>
Heart rate (beats per minute)	67.1±11.2	63.7±11.4	3.39 (2.79, 3.98)	<0.001
Peripheral BP				
Systolic (mm Hg)	133.3±22.0	135.0±19.7	-1.73 (-2.83, -0.63)	0.002
Residual systolic (mm Hg)	-1.65±3.85	1.95±4.95	-3.60 (-3.83, -3.37)	<0.001
Diastolic (mm Hg)	78.9±10.6	81.7±10.6	-2.80 (-3.36, -2.25)	<0.001
Pulse pressure (mm Hg)	54.4±17.5	53.3±14.7	1.07 (0.22, 1.93)	0.014
Residual pulse pressure (mm Hg)	-1.64±3.84	1.93±5.03	-3.57 (-3.80, -3.34)	<0.001
Central BP				
Systolic (mm Hg)	124.3±22.0	123.0±20.1	1.32 (0.21, 2.43)	0.020
Residual systolic (mm Hg)	1.66±3.79	-1.95±5.05	3.61 (3.38, 3.84)	<0.001
Diastolic (mm Hg)	80.0±10.8	82.6±10.8	-2.67 (-3.24, -2.10)	<0.001
Pulse pressure (mm Hg)	44.4±17.0	40.4±14.6	3.99 (3.15, 4.83)	<0.001
Residual pulse pressure (mm Hg)	1.71±3.58	-2.01±4.85	3.72 (3.50, 3.95)	<0.001
Mean arterial BP (mm Hg)	98.9±14.0	99.8±13.4	-0.93 (-1.65, -0.21)	0.012

Δ reported with 95% confidence interval refers to the sex difference (women minus men). Peripheral BP was measured in the supine position immediately prior to recording the tonometric signal. The residuals of peripheral systolic BP and peripheral pulse pressure were derived by regressing peripheral BP on its central counterpart, and vice versa for the residuals of central systolic BP and central pulse pressure.

Table S8. Correlation Matrix of BP with Clinical and Biochemical Variables

BP	pSBP	pDBP	pPP	cSBP	cDBP	cPP	MAP
Correlations with measured peripheral and transfer-function derived central BP							
Age	0.43*	0.06*	0.51*	0.47*	0.06*	0.59*	0.28*
BMI	0.11*	0.16*	0.04*	0.11*	0.15*	0.04*	0.14*
TC/HDLC ratio	0.04*	0.15*	-0.04*	0.04*	0.14*	-0.05*	0.09*
eGFR	-0.22*	-0.07*	-0.24*	-0.25*	-0.07*	-0.28*	-0.16*
Correlations with residual BP							
Age	-0.15*	...	-0.20*	0.26*	...	0.36*	...
BMI	0.02*	...	0.01	0.01	...	0.01	...
TC/HDLC ratio	0.04*	...	0.02	-0.03*	...	-0.04*	...
eGFR	0.07*	...	0.10*	-0.12*	...	-0.18*	...

pSBP/pDBP, peripheral systolic/diastolic BP; cSBP/cDBP, central systolic/diastolic BP; pPP/cPP, peripheral/central pulse pressure; BMI, body mass index; TC/HDLC, total/high-density lipoprotein cholesterol; eGFR, glomerular filtration rate estimated from serum creatinine (CKD-EPI formula). The residuals of peripheral systolic BP and peripheral pulse pressure were derived by regressing peripheral BP on its central counterpart, and vice versa for the residuals of central systolic BP and central pulse pressure. MAP was peripheral diastolic BP plus one third of pulse pressure (the difference between pSBP and pDBP). * $P < 0.05$.

Table S9. Incidence of Endpoints by Fourths of the Distributions of Central and Peripheral Systolic BP

Endpoints	Peripheral Systolic BP (mm Hg)				Central Systolic BP (mm Hg)			
	<120	120-130	131-145	≥146	<109	109-119	120-135	≥136
Number at risk	1402	1402	1402	1402	1402	1402	1402	1402
Primary								
Number (255)	20	37	58	140	14	36	71	134
Rate	3.72 (2.44–5.00)	5.86 (4.20–7.51)	7.24 (5.30–9.18)	17.0 (13.9–20.0)	3.92 (2.59–5.25)	5.11 (3.56–6.66)	9.03 (6.88–11.2)	16.6 (13.6–19.6)
Secondary								
Mortality								
Number (204)	30	28	46	100	27	35	41	101
Rate	5.85 (4.25–7.45)	4.93 (3.42–6.44)	6.46 (4.64–8.28)	9.50 (7.24–11.8)	7.72 (5.86–9.58)	5.71 (4.08–7.34)	5.53 (3.86–7.19)	9.40 (7.18–11.6)
Coronary								
Number (109)	11	18	27	53	9	16	35	49
Rate	2.25 (1.25–3.24)	2.76 (1.63–3.89)	3.21 (1.92–4.50)	6.38 (4.51–8.25)	2.76 (1.64–3.87)	2.40 (1.34–3.47)	4.09 (2.64–5.53)	6.44 (4.59–8.29)
Stroke								
Number (89)	7	12	19	51	4	12	23	50
Rate	1.07 (0.39–1.76)	1.71 (0.82–2.61)	2.28 (1.19–3.36)	5.71 (3.95–7.47)	1.00 (0.33–1.67)	1.41 (0.59–2.22)	3.03 (1.79–4.27)	5.50 (3.79–7.21)

The analysis includes 5608 study participants. Rates per 1000 person-years are given with 95% confidence interval. To compute 95% confidence intervals of rates, we applied the formula $R \pm 1.96 \times \sqrt{(R/T)}$, where R and T were the rate and the number of individuals used to compute the rate. All *P* values for trend across higher BP categories were significant (*P*<0.001).

Table S10. Incidence of Endpoints by Fourths of the Distributions of Central and Peripheral Pulse Pressure

Endpoints	Peripheral Pulse Pressure (mm Hg)				Central Pulse pressure (mm Hg)			
	<43	43-49	50-61	≥62	<31	31-38	39-50	≥51
Number at risk	1402	1402	1402	1402	1402	1402	1402	1402
Primary								
Number (255)	27	34	48	146	21	34	54	146
Rate	5.97 (4.39–7.54)	4.79 (3.28–6.30)	6.78 (4.90–8.66)	17.6 (14.4–20.8)	4.06 (2.74–5.38)	4.99 (3.43–6.55)	7.27 (5.35–9.20)	22.0 (18.5–25.5)
Secondary								
Mortality								
Number (204)	29	30	32	113	24	31	40	109
Rate	6.63 (4.99–8.28)	4.89 (3.37–6.41)	4.96 (3.37–6.56)	10.7 (8.21–13.1)	5.80 (4.23–7.37)	4.99 (3.45–6.54)	5.50 (3.84–7.16)	11.0 (8.53–13.4)
Coronary								
Number (109)	13	17	23	56	10	16	23	60
Rate	1.84 (0.97–2.71)	2.48 (1.39–3.56)	3.34 (2.02–4.65)	7.43 (5.36–9.51)	1.57 (0.75–2.39)	2.21 (1.18–3.25)	3.00 (1.76–4.23)	8.29 (6.15–10.4)
Stroke								
Number (89)	10	11	16	52	6	11	21	51
Rate	3.67 (2.44–4.89)	1.23 (0.46–1.99)	1.91 (0.92–2.90)	5.56 (3.78–7.35)	1.62 (0.79–2.45)	1.47 (0.63–2.32)	2.57 (1.43–3.72)	7.43 (5.42–9.45)

The analysis includes 5608 study participants. Rates per 1000 person-years are given with 95% confidence interval. To compute 95% confidence intervals of rates, we applied the formula $R \pm 1.96 \times \sqrt{(R/T)}$, where R and T were the rate and the number of individuals used to compute the rate. All P values for trend across higher BP categories were significant ($P < 0.001$).

Table S11. Association of the Primary Endpoint with the Pulsatile and Steady BP Components

BP Index ^a	Adjusted		Additionally Adjusted for Diastolic BP		Additionally Adjusted for Mean Arterial BP ^c	
	HR (95% CI) ^b	<i>P</i>	HR (95% CI) ^b	<i>P</i>	HR (95% CI) ^b	<i>P</i>
cSBP	1.50 (1.33-1.70)	<0.001	1.34 (1.12-1.59)	0.001	1.34 (0.97-1.85)	0.078
cPP	1.36 (1.19-1.54)	<0.001	1.24 (1.09-1.42)	0.001	1.09 (0.92-1.28)	0.32
pSBP	1.49 (1.33-1.67)	<0.001	1.33 (1.14-1.57)	<0.001	1.34 (1.04-1.73)	0.026
pPP	1.34 (1.19-1.51)	<0.001	1.25 (1.10-1.41)	<0.001	1.11 (0.96-1.29)	0.16

^a pSBP/pPP, peripheral systolic blood pressure/pulse pressure; cSBP/cPP, central systolic blood pressure/pulse pressure

^b The number of primary endpoints was 255 in 5608. All hazard ratios, given with 95% confidence interval, express the relative risk for a 1-SD increment in BP, accounted for cohort, sex, age, body mass index, smoking and drinking, total-to-HDL cholesterol ratio, estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.

^c Mean arterial blood pressure (BP) was peripheral diastolic BP plus one third of pulse pressure.

Table S12. Association of the Primary Endpoint with the Central and Peripheral Pulsatile BP in Various Subgroups

Endpoints BP Index ^{a,b}	Adjusted		Additionally Adjusted for cSBP or cPP ^a		Additionally Adjusted for pSBP or pPP ^a	
	HR (95% CI) ^c	P	HR (95% CI) ^{c,d,e}	P	HR (95% CI) ^{c,d,e}	P
All participants (255/5608)						
cSBP	1.50 (1.33-1.70)	<0.001	—	—	1.01 (0.53-1.93)	0.97
cPP	1.36 (1.19-1.54)	<0.001	—	—	1.12 (0.67-1.89)	0.66
pSBP	1.49 (1.33-1.67)	<0.001	1.47 (0.79-2.74)	0.22	—	—
pPP	1.34 (1.19-1.51)	<0.001	1.20 (0.74-1.96)	0.47	—	—
Baseline characteristics leading to removal from analysis						
Antihypertensive drug treatment (103/3690)						
cSBP	1.53 (1.27-1.84)	<0.001	—	—	1.27 (0.42-3.86)	0.68
cPP	1.34 (1.09-1.66)	0.006	—	—	1.19 (0.49-2.85)	0.70
pSBP	1.51 (1.26-1.81)	<0.001	1.20 (0.41-3.57)	0.74	—	—
pPP	1.33 (1.08-1.62)	0.007	1.13 (0.49-2.62)	0.77	—	—
History of CV disease (140/4816)						
cSBP	1.49 (1.26-1.76)	<0.001	—	—	1.57 (0.62-3.97)	0.34
cPP	1.34 (1.13-1.60)	0.001	—	—	1.63 (0.78-3.41)	0.20
pSBP	1.46 (1.24-1.72)	<0.001	0.95 (0.39-2.35)	0.70	—	—
pPP	1.30 (1.10-1.54)	0.003	0.83 (0.41-1.68)	0.60	—	—
eGFR <60 mL/min/1.73 m ² (182/4908)						
cSBP	1.53 (1.32-1.79)	<0.001	—	—	1.63 (0.74-3.56)	0.22
cPP	1.37 (1.16-1.61)	<0.001	—	—	1.57 (0.84-2.95)	0.16
pSBP	1.49 (1.29-1.73)	<0.001	0.94 (0.44-2.01)	0.88	—	—
pPP	1.31 (1.12-1.54)	<0.001	0.87 (0.48-1.58)	0.65	—	—
Diabetes mellitus (225/5270)						
cSBP	1.52 (1.34-1.73)	<0.001	—	—	1.03 (0.51-2.07)	0.93
cPP	1.36 (1.19-1.55)	<0.001	—	—	1.11 (0.64-1.93)	0.72
pSBP	1.50 (1.33-1.70)	<0.001	1.46 (0.75-2.86)	0.27	—	—
pPP	1.34 (1.18-1.52)	<0.001	1.22 (0.72-2.07)	0.45	—	—

^a Abbreviations: SBP/pPP, peripheral systolic blood pressure/pulse pressure; cSBP/cPP, central systolic blood pressure/pulse pressure.

^b Bracketed numbers indicate the number of primary endpoint/the number of participants retained in the analysis.

^c All hazard ratios, given with 95% confidence interval, express the relative risk for a 1-SD increment in BP and accounted for cohort, sex, age, body mass index, smoking and drinking, total-to-HDL serum cholesterol ratio, estimated glomerular filtration rate, antihypertensive drug intake, history of cardiovascular disease, and diabetes mellitus.

^d Models that included two BP indexes were constructed, using the residual method.

^e An emdash indicates not applicable.

Table S13. Correlation Matrix between Peripheral and Central BP Levels Using Peripheral Diastolic and Mean Arterial BP for Calibration (n=1203)

BP	pSBP	pDBP	pPP	cSBP	cDBP	cPP	MAP
pSBP	—						
pDBP	0.34	—					
pPP	0.89	-0.13	—				
cSBP	0.91	0.48	0.81	—			
cDBP	0.34	0.99	-0.07	0.44	—		
cPP	0.84	-0.01	0.94	0.88	-0.04	—	
MAP	0.71	0.86	0.43	0.83	0.84	0.48	—

pSBP/pDBP, peripheral systolic/diastolic BP; cSBP/cDBP, central systolic/diastolic BP; pPP/cPP, peripheral/central pulse pressure. Peripheral MAP was diastolic BP plus one third of pulse pressure (the difference between pSBP and pDBP). The correlation coefficients, derived in 1203 Flemish participants (Table S1), were all significant ($P<0.001$).

Primary Endpoint






Figure S1.

Cumulative incidence of the primary endpoint by fourths of the distributions of central (A) and peripheral (B) pulse pressure. Tabulated data are the number of participants at risk at 5-year intervals. *P* values for trend were derived by Cox proportional hazards regression. Estimates accounted for sex and age (A, B). There were no differences in hazard ratios between central (A) and peripheral (B) pulse pressure (*P*=0.90). Additional adjustment for peripheral (C) or central (D) pulse pressure removed the significance.

**Figure S2.**

Cumulative incidence of coronary endpoints by fourths of the distributions of central (A, E) and peripheral (B, F) systolic blood pressure or central (C, G) and peripheral (D, H) pulse pressure. Tabulated data are the number of participants at risk at 5-year intervals. P values for trend were derived by Cox proportional hazards regression. Estimates accounted for sex and age (A, B, C, D). Additional adjustment for peripheral (E) or central (F) systolic blood pressure or peripheral (G) or central (H) pulse pressure removed the significance.

**Figure S3.**

Cumulative incidence of stroke by fourths of the distributions of central (A, E) and peripheral (B, F) systolic blood pressure or central (C, G) and peripheral (D, H) pulse pressure. Tabulated data are the number of participants at risk at 5-year intervals. P values for trend were derived by Cox proportional hazards regression. Estimates accounted for sex and age (A, B, C, D). Additional adjustment for peripheral (E) or central (F) systolic blood pressure or peripheral (G) or central (H) pulse pressure removed the significance.




Figure S4.

Heat maps depicting the 5-year risk of the secondary endpoints in relation to central and peripheral systolic blood pressure (SBP) in 5608 study participants. Heat maps were derived by Cox proportional hazards regression. Risk estimates were standardized to the average of the distributions in the whole study population (mean or ratio) of cohort identifier, sex, age, body mass index, smoking and drinking, the total-to-HDL serum cholesterol ratio, the estimated glomerular filtration rate, intake of antihypertensive drug, history of cardiovascular disease, and diabetes mellitus. Numbers in grids **A** represent the percent of participants within each cross-classification category of central and peripheral SBP. Numbers in the other grids represent the 5-year risk of mortality (**B**), a coronary endpoint (**C**) or stroke (**D**).




Figure S5.

Heat maps depicting the 5-year risk of the secondary endpoints in relation to central and peripheral pulse pressure (PP) in 5608 study participants. Heat maps were derived by Cox proportional hazards regression. Risk estimates were standardized to the average of the distributions in the whole study population (mean or ratio) of cohort identifier, sex, age, body mass index, smoking and drinking, the total-to-HDL serum cholesterol ratio, the estimated glomerular filtration rate, intake of antihypertensive drug, history of cardiovascular disease, and diabetes mellitus. Numbers in grids **A** represent the percent of participants within each cross-classification category of central and peripheral PP. Numbers in the other grids represent the 5-year risk of mortality (**B**), a coronary endpoint (**C**) or stroke (**D**).